Evidence map›Paper›PMID 26067595›Full record

ArticleNeuroscience2015

Differential degradation of motor deficits during gradual dopamine depletion with 6-hydroxydopamine in mice.

A M Willard, R S Bouchard, A H Gittis

Abstract read
In one paragraph

Article in Neuroscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Aqueous extract ofFrontiers in neuroscience · 2024
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Deficiency ofAging · 2021
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Degree of dopaminergic degeneration measured byNeural regeneration research · 2018
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

A M WillardDepartment of Biological Sciences, Carnegie Mellon University, Pittsburgh, PA, USA; Center for the Neural Basis of Cognition, Carnegie Mellon University, Pittsburgh, PA, USA.
R S BouchardDepartment of Biological Sciences, Carnegie Mellon University, Pittsburgh, PA, USA.
A H GittisDepartment of Biological Sciences, Carnegie Mellon University, Pittsburgh, PA, USA; Center for the Neural Basis of Cognition, Carnegie Mellon University, Pittsburgh, PA, USA. Electronic address: agittis@cmu.edu.
Carnegie Mellon University · USCenter for the Neural Basis of Cognition · US

Funding

Predoctorial Training in Basic NeuroscienceT32NS007433 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MERINEY, STEPHEN D · 1998 to 2022
$8.0M
Organization and Function of Striatal Microcircuits in Health and DiseaseR00NS076524 · NINDS · CARNEGIE-MELLON UNIVERSITY · PI GITTIS, ARYN HILARY · 2013 to 2015
$736k
Organization and Function of Striatal Microcircuits in Health and DiseaseK99NS076524 · NINDS · J. DAVID GLADSTONE INSTITUTES · PI GITTIS, ARYN HILARY · 2011 to 2012
$187k
NINDS NIH HHS K99 NS076524NINDS NIH HHS R00 NS076524NINDS NIH HHS T32 NS007433
6 · The paper itself

Abstract

Parkinson's disease (PD) is a movement disorder whose cardinal motor symptoms arise due to the progressive loss of dopamine. Although this dopamine loss typically progresses slowly over time, currently there are very few animal models that enable incremental dopamine depletion over time within the same animal. This type of gradual dopamine depletion model would be useful in studies aimed at the prodromal phase of PD, when dopamine levels are pathologically low but motor symptoms have not yet presented. Utilizing the highly characterized neurotoxin 6-hydroxydopamine (6-OHDA), we have developed a paradigm to gradually deplete dopamine levels in the striatum over a user-defined time course - spanning weeks to months - in C57BL/6 mice. Dopamine depletions were achieved by administration of five low-dose injections (0.75μg) of 6-OHDA through an implanted intracranial bilateral cannula targeting the medial forebrain bundle. Levels of dopamine within the striatum declined linearly with successive injections, quantified using tyrosine hydroxylase immunostaining and high-performance liquid chromatography. Behavioral testing was carried out at each time point to study the onset and progression of motor impairments as a function of dopamine loss over time. We found that spontaneous locomotion, measured in an open field, was robust until ∼70% of striatal dopamine was lost. Beyond this point, additional dopamine loss caused a sharp decline in motor performance, reaching a final level comparable to that of acutely depleted mice. Similarly, although rearing behavior was more sensitive to dopamine loss and declined linearly as a function of dopamine levels, it eventually declined to levels similar to those seen in acutely depleted mice. In contrast, motor coordination, measured on a vertical pole task, was only moderately impaired in gradually depleted mice, despite severe impairments observed in acutely depleted mice. These results demonstrate the importance of the temporal profile of dopamine loss on the magnitude and progression of behavioral impairments. Our gradual depletion model thus establishes a new paradigm with which to study how circuits respond and adapt to dopamine loss over time, information which could uncover important cellular events during the prodromal phase of PD that ultimately impact the presentation or treatability of behavioral symptoms.

Indexed as

3,4-Dihydroxyphenylacetic AcidAdrenergic AgentsAnimalsChromatography, High Pressure LiquidDisease Models, AnimalDopamineDose-Response Relationship, DrugExploratory BehaviorFemaleHomovanillic AcidMaleMedial Forebrain BundleMiceMice, Inbred C57BLMovement DisordersNorepinephrine3,4-Dihydroxyphenylacetic Acid3-methoxytyramineAdrenergic AgentsDopamineHomovanillic AcidNorepinephrineOxidopamineSerotoninbasal gangliacompensationgradual depletionParkinson’s disease

Identifiers

PMID26067595
PMCPMC4527082
OpenAlexW611042935

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.